Thiotepa is a powerful medicine used to treat cancer. It works by attacking cancer cells. However, it is very toxic and can cause serious damage to many parts of your body, including your skin, stomach, brain, and bone marrow.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Thiotepa is a chemotherapy medicine given only in hospitals and cancer centers. In the US it is sold as Tepadina and as generic thiotepa. It is approved to treat adenocarcinoma (a cancer that starts in gland cells) of the breast or ovary, to control fluid that builds up around the lungs, heart or abdomen because of cancer (a malignant effusion), and to treat superficial papillary bladder cancer, an early form that grows on the bladder lining. At much higher doses, thiotepa is part of the "conditioning" chemotherapy given in the days before a stem cell transplant. Its approved transplant use is in children with class 3 beta-thalassemia, a severe inherited blood disorder, where it is added to busulfan and cyclophosphamide to lower the chance that the donor's cells are rejected. Doctors also use thiotepa-based conditioning off-label before transplants for other diseases, including primary central nervous system lymphoma, where it has largely replaced whole-brain radiation.
Thiotepa belongs to a group of chemotherapy drugs called alkylating agents, related to the older nitrogen mustards. It attaches chemical groups to DNA, damaging it in a way similar to radiation, so the cell cannot copy its DNA correctly and dies. Cells that divide often are hit hardest. That includes cancer cells, but also the bone marrow, the lining of the mouth and gut, hair follicles and reproductive cells, which explains most of its side effects. The effect on bone marrow is also why it is useful before a transplant. At high doses it wipes out the existing marrow and the immune cells that could reject donor cells, making room for the new stem cells to take hold.
Thiotepa is never taken at home. A clinical team prepares and gives it, and the dose is calculated from body weight or set by the specific treatment plan. How it is given depends on the reason. For breast or ovarian cancer it is infused into a vein every one to four weeks, with each dose adjusted to blood counts. For a malignant effusion it is placed directly into the affected space, usually through the same tube used to drain the fluid. For bladder cancer it is passed into the bladder through a catheter, typically once a week for four weeks, and the person holds the liquid for about two hours, changing position every so often so it reaches the whole lining. Before a transplant, high doses are infused over several hours through a central line on a set day of the conditioning schedule, alongside other chemotherapy. At these doses some of the drug leaves the body through the skin. The care team will ask the person to shower or bathe at least twice a day, have dressings changed and the skin underneath cleaned twice a day, and change bed sheets daily, continuing until 48 hours after the last dose. This reduces skin burns and peeling.
The most important effect is on the bone marrow. Thiotepa lowers white cells, which fight infection, platelets, which stop bleeding, and red cells, which carry oxygen. This carries a boxed warning, the FDA's most prominent safety warning. Blood counts are checked regularly, and after high-dose conditioning the marrow is suppressed in everyone until the transplanted cells start working, often needing transfusions and infection prevention. Fever, chills, unusual bruising or bleeding, or blood in the urine should be reported to the care team right away; a fever during low counts can be a serious infection. With standard doses, people may notice nausea, vomiting, loss of appetite, tiredness, dizziness, headache and hair thinning. Bladder treatment can cause painful or frequent urination and sometimes bleeding from the bladder lining. With transplant doses, mouth and throat sores, diarrhea, skin darkening, itching, rash and peeling (worst in skin folds and under dressings), and rises in liver tests are common. High doses can also cause serious problems that the transplant team watches for daily in the hospital. These include veno-occlusive disease, a blockage of small veins in the liver that causes weight gain, fluid buildup and jaundice, and effects on the brain such as confusion, drowsiness or seizures. Allergic reactions, including rarely anaphylaxis, can occur during or after an infusion.
Thiotepa damages DNA in healthy cells too, so it carries a boxed warning that it may cause cancer. People treated with it have a higher risk of developing a second, different cancer later in life. This is one reason long-term follow-up continues after treatment ends. Live vaccines, which contain a weakened form of a virus or bacterium, must not be given until the immune system has recovered, which after a transplant can take a long time. The treating team decides when vaccinations restart. Some medicines change how the body processes thiotepa and should be avoided if possible, including the antifungal itraconazole, the antibiotic clarithromycin, the HIV medicine ritonavir, the tuberculosis antibiotic rifampin and the seizure medicine phenytoin. Anyone needing surgery or anesthesia soon after treatment should tell the team about recent chemotherapy. Thiotepa can seriously harm a developing baby. A pregnancy test is done before treatment. Women who could become pregnant should use effective contraception during treatment and for 6 months after the last dose, and men with partners who could become pregnant should use contraception for 1 year after. Breastfeeding is not advised during treatment. Thiotepa can reduce or end fertility in both men and women, so sperm banking or other fertility preservation is worth discussing before treatment starts.
What thiotepa feels like depends heavily on why it is used. A course of bladder instillations is usually given in an outpatient clinic, with the main effects being bladder irritation and checks of blood counts, especially if courses are repeated. Infusions for breast or ovarian cancer involve blood tests before each dose, and the dose or timing may change if counts are low. Transplant conditioning is a hospital stay. Blood counts fall to very low levels over the following days and recover once the new stem cells engraft and begin making blood cells, during which people are at high risk of infection and may need transfusions, antibiotics and careful skin and mouth care. Liver tests, weight and mental alertness are checked closely in the first month. Recovery of the immune system takes much longer, so follow-up continues for months to years, including revaccination and monitoring for late effects such as infertility and second cancers.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Thiotepa, what you've noticed, or ask the community a question.